Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15783MR)

This product GTTS-WQ15783MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Hematologic-blood cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15783MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13038MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ14784MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ13764MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ11285MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ81MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ12398MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ3940MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ12312MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW